

Supporting Information

Schünke et al. 10.1073/pnas.1015890108

SI Materials and Methods

NMR Sample Preparation. MloK1 CNBD was expressed as a fusion protein with glutathione S-transferase. Details of cloning, expression of [U - ^{15}N , ^{13}C] or [U - ^{15}N]-isotopically labeled recombinant CNBD protein, and cell lysis were described previously (1, 2). After cell lysis soluble and insoluble fractions were separated by centrifugation ($50,000 \times g$ for 30 min at 4°C). The supernatant was passed over a glutathione-Sepharose 4B column (30 ml bed volume) equilibrated with cold $1 \times$ PBS buffer (pH 7.4). After the supernatant has been applied, the column was washed with 10 column volumes of cold $1 \times$ PBS binding buffer and about 8 liter washing buffer (50 mM MES, pH 6.5, 100 μM EDTA, 50 mM NaCl) overnight. Furthermore the column was washed with $1 \times$ PBS buffer followed by incubation with thrombin for cleavage of the CNBD domain from the GST tag. Thrombin cleavage yielded the isolated cyclic nucleotide binding domain (Q216 to A355) with additional glycine and serine residues at the N terminus. Cleaved CNBD protein was eluted with two and a half column volumes of $1 \times$ PBS buffer. Cleavage and final purity of CNBD protein after affinity chromatography were evaluated by SDS/PAGE analysis. The buffer was immediately exchanged to buffer A (10 mM MES, pH 6, 100 μM EDTA) on a HiPrep 26/10 desalting column mounted on an Äkta purifier system (GE Healthcare). The desalting step was monitored at 280 nm and 260 nm. Performance of the desalting step was observed by measuring the conductivity. Subsequently ion-exchange chromatography was used to separate both domains, cAMP-free and cAMP-bound CNBD. A cation-exchange chromatography column Mono S HR 5/5 (GE Healthcare) was used and the absorption was monitored at 260 and 280 nm. Buffer A was used as binding buffer and elution was directed with buffer A supplied with 1 M NaCl (buffer B). cAMP-free and -bound CNBD protein was separately eluted and the respective fractions were pooled. cAMP-free and -bound CNBD were dialyzed against buffer C (10 mM potassium phosphate, pH 7, 100 mM potassium chloride, 100 μM EDTA, 0.02% (w/v) sodium azide) and buffer D (10 mM Tris/HCl, pH 7, 100 mM sodium chloride, 200 μM EDTA, 0.02% (w/v) sodium azide), respectively. CNBD was concentrated with an Amicon stirred system (Ultracel PL-3, 3 kDa molecular weight cutoff, Millipore). During the final concentration steps the buffer was exchanged by four volumes of the respective NMR buffer including 5% (v/v) $^2\text{H}_2\text{O}$ and deuterated Tris (D11, 98%, Cambridge Isotope Laboratories)/HCl. The protein concentration was determined with Bradford assay (BioRad). NMR samples contained 0.5 mM [U - ^{15}N] or [U - ^{15}N , ^{13}C] labeled CNBD in aqueous solution.

NMR Spectroscopy. Nuclear Overhauser Effect (NOE) distance constraints for structure calculations were derived from three-dimensional (^1H - ^1H - ^{15}N)-NOESY-HSQC (3) (120 ms mixing time), aliphatic (^1H - ^{13}C - ^1H)-HSQC-NOESY (100 ms mixing time), aromatic (^1H - ^{13}C - ^1H)-HSQC-NOESY (4) (140 ms mixing time) and two-dimensional aromatic (^1H - ^{13}C - ^1H)-HSQC-NOESY (100 ms mixing time) experiments.

For the characterization of overall and internal motions, ^{15}N longitudinal (R_1) and transverse (R_2) relaxation rates, together with the steady-state $\{^1\text{H}\}$ - ^{15}N -NOE, were recorded at 298 K on a [U - ^{15}N] labeled protein sample using standard methods at 600 MHz and 800 MHz proton frequency. Peak integral values were obtained by fitting signals to an adjustable "peak model"

shape using the program CARA (5). A superposition of Lorentz and Gauss functions was employed and adjusted manually and independently for both spectral dimensions. For ^{15}N R_1 measurement relaxation delay values of 11, 65, 141, 249, 380, 542, 758, and 1192 ms were applied. For R_2 delays of 10, 30, 50, 70, 90, 110, and 150 ms were used. Data of R_1 and R_2 relaxation experiments were fitted to a mono-exponential decay using the program CurveFit (A.G. Palmer, Columbia University). The correlation time was determined for an isotropic tumbling model using the TENSOR2 (6) package. $\{^1\text{H}\}$ - ^{15}N -NOE-TROSY spectra (7–9) were acquired with 2.5 s proton saturation.

Proton-deuterium exchange experiments were performed at 298 K. Slowly exchanging amide protons were identified by sequentially recording a set of two-dimensional SOFAST (^{15}N - ^1H)-HMQC (10) spectra using 0.5 mM [U - ^{15}N] labeled MloK1 CNBD samples, either in the absence or presence of cAMP, which were lyophilized and resolved in deuterium oxide. The first (^{15}N - ^1H)-HSQC data points were obtained after a delay of roughly 5 minutes, the last spectrum was recorded after 14 hours for the cAMP-free and 24 hours for the cAMP-bound CNBD. Total measuring time of each experiment was 10.83 and 6.67 minutes for the cAMP-free and -bound MloK1 CNBD, respectively. Relative cross-peak intensities were extracted and fitted using a mono-exponential decay to determine the exchange rate (k_{ex}).

Titration experiments were carried out to a 0.2 mM [U - ^{15}N] labeled unliganded MloK1 CNBD sample by stepwise addition of small aliquots of concentrated cAMP stock solutions (Sigma-Aldrich). Eight (^{15}N - ^1H)-HSQC spectra were recorded with increasing ligand concentrations of 5, 10, 25, 50, 75, 100, 250, and 500 μM cAMP.

Data Evaluation and Structure Calculation. Based on an almost complete assignment of ^1H , ^{15}N , and ^{13}C resonances of cAMP-free CNBD, NOE cross peak assignments were obtained by an iterative procedure using a combination of manual and automatic steps. CARA was used to evaluate NOE spectra and to manually assign nearly all of the apparently unambiguous NOE distance constraints. NOE cross-peak intensities were classified as strong, medium and weak, corresponding to upper limit distance constraints of 2.7, 3.8, and 5.5 Å, respectively. Intensities of NOE cross-peaks between protons of known distances were used for calibration. For NOE cross-peaks involving methyl groups upper limit distance constraints of 2.9, 4.0, and 5.7 Å for strong, medium or weak interactions were used. Structure calculations were performed using the program CYANA (11). CYANA runs were performed according to the protocol for simulated annealing with 100 randomly generated starting conformations, 25,000 steps torsion angle dynamics and subsequent 2,000 conjugate gradients minimization steps. Using only manually assigned NOE cross-peaks an initial fold of the protein was calculated. Additional NOE cross-peaks were automatically assigned in an iterative approach using ATNOS/CANDID (12, 13) algorithms in combination with CYANA, giving the resonance assignments, all manually assigned NOE cross-peaks and all three-dimensional NOESY spectra as input. The standard protocol with seven cycles of peak picking, cross-peak assignment, and subsequent structure calculation with CYANA was applied. In the final step dihedral angle restraints for backbone Φ and Ψ angles were included that were derived from H^α , C^α , C^β , C^γ , and N chemical shifts using the pro-





Fig. S7. Comparison of cAMP-bound and -free MloK1 CNBD solution structures and monomers of eukaryotic HCN2 CNBD crystal structures. The solution structure of the cAMP-bound and -free wild-type MloK1 CNBD (A) is superimposed onto each other (B). The cAMP-bound and -free CNBD structure of the HCN2 channel (C) is superimposed onto each other (D). The cAMP-bound and -free MloK1 CNBD solution structure is superimposed onto the cAMP-bound and -free CNBD crystal structure of the HCN2 channel (E and F). The CNBDs were taken from PDB ID codes 2K0G (MloK1 CNBD holo state (1), helices are shown in green), 1Q43 (HCN2 CNBD holo state (2), helices are shown in light yellow), 2KXL (MloK1 CNBD apo state, helices are shown in red and loop region in yellow), and 3FFQ (HCN2 CNBD apo state (3), helices are shown in light blue and loop region in orange). β strands are shown in blue and cAMP in stick model. The least-square superposition of the structures was done using the backbone atoms of the β roll forming strands. MloK1 CNBD backbone atoms of the amino- and carboxy-terminal ends (residues Q216-R220 and A351-A355) are not shown.

- Schünke S, Stoldt M, Novak K, Kaupp UB, Willbold D (2009) Solution structure of the *Mesorhizobium loti* K1 channel cyclic nucleotide-binding domain in complex with cAMP. *EMBO Rep* 10:729–735.
- Zagotta WN, et al. (2003) Structural basis for modulation and agonist specificity of HCN pacemaker channels. *Nature* 425:200–205.
- Taraska JW, Puljung MC, Olivier NB, Flynn GE, Zagotta WN (2009) Mapping the structure and conformational movements of proteins with transition metal ion FRET. *Nat Methods* 6:532–537.



Movie S1. Structure comparison of cAMP-free and -bound wild-type MloK1 CNBD—an animation to illustrate the large conformational rearrangement on ligand binding. The CNBD is shown in ribbon representation and the cAMP molecule is shown as stick model.

[Movie S1 \(GIF\)](#)

